Celldex Therapeutics, Inc.
CLDX
$28.81
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 121.00K | -- | 730.00K | 695.00K | 1.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 121.00K | -- | 730.00K | 695.00K | 1.18M |
| Cost of Revenue | 75.33M | 62.93M | 54.20M | 52.61M | 46.94M |
| Gross Profit | -75.21M | -62.93M | -53.47M | -51.92M | -45.76M |
| SG&A Expenses | 11.94M | 10.69M | 10.39M | 10.82M | 10.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.27M | 73.62M | 64.59M | 63.43M | 57.20M |
| Operating Income | -87.15M | -73.62M | -63.86M | -62.74M | -56.03M |
| Income Before Tax | -81.32M | -67.04M | -56.60M | -53.80M | -47.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -81.32M | -67.04M | -56.60M | -53.80M | -47.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.32M | -67.04M | -56.60M | -53.80M | -47.09M |
| EBIT | -87.15M | -73.62M | -63.86M | -62.74M | -56.03M |
| EBITDA | -86.34M | -72.79M | -62.98M | -61.87M | -55.21M |
| EPS Basic | -1.22 | -1.01 | -0.85 | -0.81 | -0.71 |
| Normalized Basic EPS | -0.76 | -0.63 | -0.53 | -0.51 | -0.44 |
| EPS Diluted | -1.22 | -1.01 | -0.85 | -0.81 | -0.71 |
| Normalized Diluted EPS | -0.76 | -0.63 | -0.53 | -0.51 | -0.44 |
| Average Basic Shares Outstanding | 66.49M | 66.42M | 66.39M | 66.38M | 66.35M |
| Average Diluted Shares Outstanding | 66.49M | 66.42M | 66.39M | 66.38M | 66.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |